NEW YORK – The European Medicines Agency (EMA) granted conditional approval on Wednesday for trastuzumab deruxtecan (Daiichi Sankyo/AstraZeneca's Enhertu) as a treatment for patients with metastatic, HER2-positive breast cancer who have previously received two or more anti-HER2 treatments.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.